Comparative Pharmacology
Head-to-head clinical analysis: LENVATINIB versus NINTEDANIB ESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LENVATINIB versus NINTEDANIB ESYLATE.
LENVATINIB vs NINTEDANIB ESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lenvatinib is a kinase inhibitor that inhibits the receptor tyrosine kinases (RTKs) including VEGFR1 (FLT1), VEGFR2 (KDR), VEGFR3 (FLT4), FGFR1, FGFR2, FGFR3, FGFR4, PDGFRα, KIT, and RET. It also inhibits the kinase activities of other RTKs involved in tumor angiogenesis and tumor growth.
Nintedanib esylate is a tyrosine kinase inhibitor that binds competitively to the ATP-binding pocket of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-α, PDGFR-β), and fibroblast growth factor receptors (FGFR-1, FGFR-2, FGFR-3). This inhibition blocks downstream signaling pathways involved in angiogenesis and fibrosis.
24 mg orally once daily for differentiated thyroid carcinoma; 8 mg twice daily or 12 mg once daily in combination with everolimus for renal cell carcinoma; 12 mg once daily in combination with pembrolizumab for advanced endometrial carcinoma.
150 mg orally twice daily, 12 hours apart, taken with food.
None Documented
None Documented
Clinical Note
moderateLenvatinib + Digoxin
"Lenvatinib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateLenvatinib + Digitoxin
"Lenvatinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateLenvatinib + Deslanoside
"Lenvatinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateLenvatinib + Acetyldigitoxin
"Lenvatinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Approximately 28 hours (range 22-35 hours); supports once-daily dosing with steady-state achieved in ~5-7 days.
Terminal elimination half-life is approximately 10 hours in patients with IPF; steady state reached within 7 days.
Fecal (approximately 64% of dose) and renal (approximately 25% of dose, with <2% as unchanged drug).
Biliary/fecal: >90% (unchanged and metabolites); Renal: <1%
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor